PE20221465A1 - Anticuerpos anti-trem2 y metodos para utilizarlos - Google Patents
Anticuerpos anti-trem2 y metodos para utilizarlosInfo
- Publication number
- PE20221465A1 PE20221465A1 PE2022001437A PE2022001437A PE20221465A1 PE 20221465 A1 PE20221465 A1 PE 20221465A1 PE 2022001437 A PE2022001437 A PE 2022001437A PE 2022001437 A PE2022001437 A PE 2022001437A PE 20221465 A1 PE20221465 A1 PE 20221465A1
- Authority
- PE
- Peru
- Prior art keywords
- trem2
- methods
- antibody
- polypeptide
- trem2 antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960663P | 2020-01-13 | 2020-01-13 | |
| US202063070728P | 2020-08-26 | 2020-08-26 | |
| US202063091717P | 2020-10-14 | 2020-10-14 | |
| PCT/US2021/013200 WO2021146256A1 (en) | 2020-01-13 | 2021-01-13 | Anti-trem2 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221465A1 true PE20221465A1 (es) | 2022-09-21 |
Family
ID=76760857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001437A PE20221465A1 (es) | 2020-01-13 | 2021-01-13 | Anticuerpos anti-trem2 y metodos para utilizarlos |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11124567B2 (he) |
| EP (1) | EP4090682A1 (he) |
| JP (1) | JP2023512450A (he) |
| KR (1) | KR20220131246A (he) |
| CN (1) | CN115279790A (he) |
| AU (1) | AU2021208482A1 (he) |
| BR (1) | BR112022013756A2 (he) |
| CA (1) | CA3166385A1 (he) |
| CO (1) | CO2022009744A2 (he) |
| IL (1) | IL294655A (he) |
| MX (1) | MX2022008582A (he) |
| PE (1) | PE20221465A1 (he) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3583120T5 (da) | 2017-02-17 | 2024-09-02 | Denali Therapeutics Inc | Modificerede transferrinreceptorbindende polypeptider |
| CA3076369A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| EP4081536A1 (en) | 2019-12-23 | 2022-11-02 | Denali Therapeutics Inc. | Progranulin variants |
| CN116916947A (zh) | 2020-10-14 | 2023-10-20 | 戴纳立制药公司 | 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法 |
| WO2023192288A1 (en) * | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN117624360A (zh) * | 2022-08-26 | 2024-03-01 | 南京融捷康生物科技有限公司 | 一种抗trem2的单域抗体及其用途 |
| WO2024052343A1 (en) | 2022-09-06 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Trem-2 agonists for the treatment of marfan syndrome |
| CN116041481B (zh) * | 2022-09-13 | 2024-01-19 | 北京湃德智健科技有限公司 | 一种用于检测trem2自身抗体的抗原多肽及其应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| BRPI1013688A8 (pt) | 2009-03-05 | 2017-02-14 | Abbott Lab | Proteínas de ligação de il-17. |
| PT2992013T (pt) | 2013-04-29 | 2020-03-05 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado |
| US11261262B2 (en) | 2013-09-03 | 2022-03-01 | Novimmune Sa | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| CN105218669A (zh) | 2014-06-10 | 2016-01-06 | 河北翰林生物科技有限公司 | 制备抗人r47h-trem2突变体的人单克隆抗体的方法 |
| CN107106679B (zh) | 2014-08-08 | 2022-07-26 | 艾利妥 | 抗trem2抗体及其使用方法 |
| MX2017004007A (es) | 2014-09-28 | 2018-05-07 | Univ California | Modulacion de celulas mieloides estimulantes y no estimulantes. |
| WO2017058866A1 (en) | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| US20190330335A1 (en) | 2015-10-06 | 2019-10-31 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| US11066456B2 (en) | 2016-02-25 | 2021-07-20 | Washington University | Compositions comprising TREM2 and methods of use thereof |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| AU2017300040A1 (en) | 2016-07-22 | 2019-01-24 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | TREM2 cleavage modulators and uses thereof |
| CA3048224A1 (en) | 2016-12-23 | 2018-06-28 | Bluefin Biomedicine, Inc. | Anti-sez6l2 antibodies and antibody drug conjugates |
| EP3570883A2 (en) | 2017-01-17 | 2019-11-27 | Yeda Research and Development Co. Ltd | Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells |
| MX2019009817A (es) * | 2017-02-17 | 2019-11-21 | Denali Therapeutics Inc | Anticuerpos anti-tau y metodos de uso de los mismos. |
| US10457717B2 (en) * | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| DK3583120T5 (da) * | 2017-02-17 | 2024-09-02 | Denali Therapeutics Inc | Modificerede transferrinreceptorbindende polypeptider |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| CN110945018A (zh) | 2017-07-27 | 2020-03-31 | 诺华股份有限公司 | 抗脱落酶的trem2变体 |
| JP2020533948A (ja) | 2017-08-03 | 2020-11-26 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体及びその使用方法 |
| HUE063021T2 (hu) * | 2017-08-10 | 2023-12-28 | Denali Therapeutics Inc | Mesterségesen elõállított transzferrin receptor-kötõ polipeptidek |
| WO2019055841A1 (en) | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| CA3076369A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| US20210186917A1 (en) | 2017-10-17 | 2021-06-24 | The Translational Genomics Research Institute | Trem2 agonists for the stimulation of microglia and methods of identification |
| WO2019094608A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| JP7311512B2 (ja) | 2017-12-12 | 2023-07-19 | パイオニア イミュノセラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及び関連する方法 |
| CN111741977A (zh) | 2018-01-10 | 2020-10-02 | 戴纳立制药公司 | 转铁蛋白受体结合性多肽和其用途 |
| MX2020012518A (es) | 2018-06-18 | 2021-02-16 | Denali Therapeutics Inc | Proteinas de fusion que comprenden progranulina. |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| EP3850007A4 (en) | 2018-08-16 | 2022-08-10 | Denali Therapeutics Inc. | MODIFIED B-SPECIFIC PROTEINS |
| JP2021534220A (ja) | 2018-08-22 | 2021-12-09 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法 |
| CA3111569A1 (en) | 2018-09-11 | 2020-03-19 | Washington University | Anti-trem-2 agonist antibodies |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| KR102156165B1 (ko) | 2018-10-29 | 2020-09-15 | 재단법인대구경북과학기술원 | 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| JP2022513114A (ja) | 2018-11-26 | 2022-02-07 | デナリ セラピューティクス インコーポレイテッド | 脂質代謝調節不全の治療方法 |
| EP3898691A4 (en) | 2018-12-10 | 2022-09-14 | Mor Research Applications | TREM2 ANTIBODIES AND USES THEREOF |
| JP2022513735A (ja) | 2018-12-10 | 2022-02-09 | デナリ セラピューティクス インコーポレイテッド | リソソーム蓄積障害のバイオマーカー及びその使用方法 |
| AU2019397479A1 (en) | 2018-12-11 | 2021-07-29 | Pionyr Immunotherapeutics, Inc. | Methods of using anti-TREM2 antibodies |
| EA202192294A1 (ru) | 2019-02-20 | 2021-12-24 | Денали Терапьютикс Инк. | Антитела к trem2 и способы их применения |
| WO2020194317A1 (en) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
| MX2021011612A (es) | 2019-04-03 | 2021-12-10 | Denali Therapeutics Inc | Formulaciones de moleculas proteicas que comprenden iduronato 2-sulfatasa. |
-
2021
- 2021-01-13 EP EP21704639.0A patent/EP4090682A1/en active Pending
- 2021-01-13 MX MX2022008582A patent/MX2022008582A/es unknown
- 2021-01-13 AU AU2021208482A patent/AU2021208482A1/en active Pending
- 2021-01-13 BR BR112022013756A patent/BR112022013756A2/pt unknown
- 2021-01-13 IL IL294655A patent/IL294655A/he unknown
- 2021-01-13 PE PE2022001437A patent/PE20221465A1/es unknown
- 2021-01-13 CA CA3166385A patent/CA3166385A1/en active Pending
- 2021-01-13 KR KR1020227025637A patent/KR20220131246A/ko unknown
- 2021-01-13 JP JP2022542652A patent/JP2023512450A/ja active Pending
- 2021-01-13 CN CN202180008986.5A patent/CN115279790A/zh active Pending
- 2021-01-15 US US17/151,006 patent/US11124567B2/en active Active
- 2021-09-17 US US17/478,587 patent/US20220177576A1/en active Pending
-
2022
- 2022-07-12 CO CONC2022/0009744A patent/CO2022009744A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4090682A1 (en) | 2022-11-23 |
| US20210214438A1 (en) | 2021-07-15 |
| US11124567B2 (en) | 2021-09-21 |
| AU2021208482A1 (en) | 2022-07-21 |
| JP2023512450A (ja) | 2023-03-27 |
| BR112022013756A2 (pt) | 2022-10-11 |
| CO2022009744A2 (es) | 2022-07-19 |
| US20220177576A1 (en) | 2022-06-09 |
| IL294655A (he) | 2022-09-01 |
| MX2022008582A (es) | 2022-08-10 |
| KR20220131246A (ko) | 2022-09-27 |
| CA3166385A1 (en) | 2021-07-22 |
| CN115279790A (zh) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221465A1 (es) | Anticuerpos anti-trem2 y metodos para utilizarlos | |
| PE20211284A1 (es) | Anticuerpos anti-nkg2a y usos de los mismos | |
| PE20231067A1 (es) | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos | |
| EA202092460A1 (ru) | Антитела к ox40 и способы применения | |
| HRP20191095T1 (hr) | Humanizirano anti kallikrein-2 antitijelo | |
| MX2020008795A (es) | Anti cuerpos anti tigit y usos de los mismos. | |
| PE20211767A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g | |
| JP2018512379A5 (he) | ||
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| EA201691225A1 (ru) | Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение | |
| PE20140448A1 (es) | Moleculas de union biespecificas que se unen a vegf y ang2 | |
| PE20090329A1 (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
| CO6251370A2 (es) | Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la misma | |
| ECSP21010450A (es) | Anticuerpos antisortilina y métodos para su uso | |
| RU2014113046A (ru) | Профилактика и лечение патологических состояний глаз, вызванных комплементом | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| PE20230444A1 (es) | Anticuerpos | |
| AR079458A2 (es) | Anticuerpo monoclonal quimerico que se une a cd45 | |
| EA202092420A1 (ru) | Антитело против pd-l1 и его применение | |
| EA202191359A1 (ru) | Антагонистические моноклональные антитела к cd40 и их применения | |
| PE20221449A1 (es) | Agentes de union a cd8 y usos de los mismos | |
| PE20231080A1 (es) | Anticuerpos que se unen a cd3 y cd19 | |
| PE20230839A1 (es) | Agentes de union a lair-1 y metodos para su uso | |
| PE20231187A1 (es) | Anticuerpos anti-par-2 y metodos de uso de los mismos | |
| CO2022010294A2 (es) | Anticuerpos cd163 o proteinas de union |